1.河北中医药大学 研究生学院,石家庄 050091
2.河北中医药大学 第一附属医院/河北省中医院,石家庄 050011
郭世龙,在读硕士,从事中医药治疗肾脏病研究,E-mail:guoshilong1376@163.com
郭登洲,博士,教授,从事中医药治疗肾脏病研究,E-mail:guodengzhou@sohu.com
收稿:2025-12-02,
修回:2026-01-07,
录用:2026-01-09,
网络首发:2026-01-13,
纸质出版:2026-03-20
移动端阅览
郭世龙,李睿嘉,王子轩等.基于TLR4/NF-κB p65/NLRP3信号通路探讨当归芍药散改善糖尿病肾病小鼠炎症反应机制[J].中国实验方剂学杂志,2026,32(06):19-27.
GUO Shilong,LI Ruijia,WANG Zixuan,et al.Mechanism of Danggui Shaoyaosan in Improving Inflammatory Response in Mice with Diabetic Kidney Disease Based on TLR4/p65/NLRP3 Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2026,32(06):19-27.
郭世龙,李睿嘉,王子轩等.基于TLR4/NF-κB p65/NLRP3信号通路探讨当归芍药散改善糖尿病肾病小鼠炎症反应机制[J].中国实验方剂学杂志,2026,32(06):19-27. DOI: 10.13422/j.cnki.syfjx.20260119.
GUO Shilong,LI Ruijia,WANG Zixuan,et al.Mechanism of Danggui Shaoyaosan in Improving Inflammatory Response in Mice with Diabetic Kidney Disease Based on TLR4/p65/NLRP3 Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2026,32(06):19-27. DOI: 10.13422/j.cnki.syfjx.20260119.
目的
2
观察当归芍药散对自发性糖尿病db/db小鼠肾脏组织中Toll样受体4/核转录因子-
κ
B p65/NOD样蛋白受体3(TLR4/NF-
κ
B p65/NLRP3)信号通路的表达,探讨当归芍药散缓解糖尿病肾病(DKD)炎症的可能作用机制。
方法
2
将30只db/db小鼠按随机数字表法分为5组(
n
=6):模型组,当归芍药散低(16.77 g·kg
-1
·d
-1
)、中(33.54 g·kg
-1
·d
-1
)、高(67.08 g·kg
-1
·d
-1
)3个剂量干预组及厄贝沙坦组(0.025 g·kg
-1
·d
-1
);同时,以db/m小鼠(
n
=6)作为正常组。干预8周后,检测小鼠体质量、空腹血糖(FBG)、24 h尿蛋白(24 h-UTP)及血肌酐浓度(SCr);苏木素-伊红(HE)染色、马松(Masson)染色和过碘酸-希夫染色(PAS)染色对肾脏组织进行病理学观察和分析;蛋白免疫印迹法(Western blot)、实时荧光定量聚合酶链式反应(Real-time PCR)检测TLR4、NF-
κ
B p65、NLRP3和肿瘤坏死因子-
α
(TNF-
α
)、白细胞介素(IL)-1
β
、IL-6、IL-10、IL-18蛋白及mRNA表达水平;免疫组化法(IHC)检测肾脏组织中TLR4、NF-
κ
B p65、NLRP3蛋白的表达。
结果
2
与正常组比较,模型组小鼠体质量、FBG、24 h-UTP、SCr表达升高(
P
<
0.05);肾脏结构紊乱,基底膜增厚,间质可见较多炎细胞浸润;TLR4、NF-
κ
B p65、NLRP3、TNF-
α
、IL-1
β
、IL-6、IL-18表达增加,IL-10表达降低(
P
<
0.05);与模型组比较,给药组大鼠FBG、24 h-UTP、SCr水平均有不同程度降低,肾脏组织病理损伤明显改善,TLR4、NF-
κ
B p65、NLRP3、TNF-
α
、IL-1
β
、IL-6、IL-18表达降低,IL-10表达升高(
P
<
0.05)。
结论
2
当归芍药散可能通过调节TLR4/NF-
κ
B p65/NLRP3信号通路减轻肾脏炎症反应并降低尿蛋白排泄,进而延缓DKD的疾病进展。
Objective
2
To investigate the effect of Danggui Shaoyaosan on the expression of Toll-like receptor 4/nucl
ear factor-kappa B p65/NOD-like receptor protein 3 (TLR4/NF-
κ
B p65/NLRP3) signaling pathway in the renal tissues of db/db mice with spontaneous diabetes, and to explore the potential mechanism by which Danggui Shaoyaosan alleviates inflammation in diabetic kidney disease (DKD).
Methods
2
Thirty db/db mice were divided into five groups: A model group, Danggui Shaoyaosan low- (16.77 g·kg
-1
·d
-1
), medium- (33.54 g·kg
-1
·d
-1
), and high-dose (67.08 g·kg
-1
·d
-1
) intervention groups, as well as an irbesartan group (0.025 g·kg
-1
·d
-1
) by the random number table method, with 6 mice in each group. Additionally, 6 db/m mice were assigned to the normal group. After 8 weeks of intervention, the following parameters were determined by corresponding methods: body weight, fasting blood glucose (FBG), 24-hour urinary protein (24 h-UTP), and serum creatinine (SCr) levels, renal histopathological analysis by hematoxylin-eosin (HE) staining, Masson staining, and periodic acid-Schiff (PAS) staining, the protein and mRNA expression levels of TLR4, NF-
κ
B p65, NLRP3, tumor necrosis factor-alpha (TNF-
α
), interleukin-1
β
(IL-1
β
), interleukin-6 (IL-6), interleukin-10 (IL-10), and interleukin-18 (IL-18) by Western blot and Real-time quantitative polymerase chain reaction (Real-time PCR), as well as TLR4, NF-
κ
B p65, and NLRP3 protein expression in renal tissues by immunohistochemistry (IHC).
Results
2
Compared with the normal group, the model group exhibited increased body weight, FBG, 24 h-UTP, and SCr levels (
P
<
0.05); disordered renal structure, thickened basement membrane, and interstitial inflammatory cell infiltration, elevated TLR4, NF-
κ
B p65, NLRP3, TNF-
α
, IL-1
β
, IL-6, and IL-18 expression; as well as decreased IL-10 expressio
n (
P
<
0.05). Compared with the model group, these pathological changes and biochemical abnormalities were reversed in the medicine intervention groups to varying degrees (
P
<
0.05).
Conclusion
2
Danggui Shaoyaosan may delay DKD progression by alleviating renal inflammatory response and reducing urinary protein excretion via modulating the TLR4/NF-
κ
B p65/NLRP3 signaling pathway.
KOURTIDOU C , TZIOMALOS K . Advances in the pathogenesis of diabetic kidney disease [J]. Int J Mol Sci , 2024 , 25 ( 8 ): 4563 .
CLEVELAND K H , SCHNELLMANN R G . Pharmacological targeting of mitochondria in diabetic kidney disease [J]. Pharmacol Rev , 2023 , 75 ( 2 ): 250 - 262 .
SAWAF H , THOMAS G , TALIERCIO J J , et al . Therapeutic advances in diabetic nephropathy [J]. J Clin Med , 2022 , 11 ( 2 ): 378 .
SAEEDI P , PETERSOHN I , SALPEA P , et al . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:Results from the international diabetes federation diabetes atlas,9th edition [J]. Diabetes Res Clin Pract , 2019 , 157 : 107843 .
HOOGEVEEN E K . The epidemiology of diabetic kidney disease [J]. Kidney Dial , 2022 , 2 ( 3 ): 433 - 442 .
RUI Z , JIA Z , ZHIJUN D , et al . PGC1 α plays a pivotal role in renal fibrosis via regulation of fatty acid metabolism in renal tissue [J]. J Cent South Univ:Med Sci , 2022 , 47 ( 6 ): 786 - 793 .
LIU Y , ZHANG M , ZENG L , et al . Wogonin upregulates SOCS3 to alleviate the injury in diabetic nephropathy by inhibiting TLR4-mediated JAK/STAT/AIM2 signaling pathway [J]. Mol Med , 2024 , 30 ( 1 ): 78 .
BAYAN N , YAZDANPANAH N , REZAEI N . Role of toll-like receptor 4 in diabetic retinopathy [J]. Pharmacol Res , 2022 , 175 : 105960 .
CHEN L , LIN X , LEI Y , et al . Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF- κ B p65/HK2 signalling [J]. J Exp Clin Cancer Res:CR , 2022 , 41 ( 1 ): 329 .
BLEVINS H M , XU Y , BIBY S , et al . The NLRP3 inflammasome pathway:A review of mechanisms and inhibitors for the treatment of inflammatory diseases [J]. Front Aging Neurosci , 2022 , 14 : 879021 .
YANG J , LI C , LIU Y , et al . Using network pharmacology to explore the mechanism of Danggui Shaoyaosan in the treatment of diabetic kidney disease [J]. Front Pharmacol , 2022 , 13 : 832299 .
梅莎莎 , 宋恩峰 , 项琼 . 当归芍药散联合氯沙坦治疗早期糖尿病肾病临床观察 [J]. 辽宁中医药大学学报 , 2016 , 18 ( 2 ): 101 - 103 .
MEI S S , SONG E F , XIANG Q . Clinical observation of Danggui Shaoyao powder combined with losartan in treating early diabetic nephropathy [J]. J Liaoning Univ Tradit Chin Med , 2016 , 18 ( 2 ): 101 - 103 .
林文云 , 丘余良 . 真武汤合当归芍药散治疗糖尿病肾病(G4A3期)水肿患者临床观察及对尿AQP2的影响 [J]. 亚太传统医药 , 2024 , 20 ( 10 ): 65 - 69 .
LIN W Y , QIU Y L . Clinical observation of Zhenwu decoction combined with Danggui Shaoyao powder in treating diabetic nephropathy (G4A3 stage) edema patients and its effect on urinary AQP2 [J]. Asia-Pac Tradit Med , 2024 , 20 ( 10 ): 65 - 69 .
李佳欣 , 周丽雅 , 张益蒴 , 等 . 加味升降散调节PINK1/Parkin信号通路激活糖尿病肾病线粒体自噬的机制 [J]. 中国实验方剂学杂志 , 2025 , 31 ( 12 ): 121 - 128 .
LI J X , ZHOU L Y , ZHANG Y S , et al . Mechanism of modified Shengjiang San in regulating PINK1/Parkin signaling pathway to activate mitophagy in diabetic nephropathy [J]. Chin J Exp Tradit Med Form , 2025 , 31 ( 12 ): 121 - 128 .
吴源陶 , 王智槟 , 傅馨莹 , 等 . 参芪地黄汤介导ACSL4/LPCAT3/ALOX15轴抑制花生四烯酸相关性铁死亡改善小鼠糖尿病肾病肾功能 [J]. 中国实验方剂学杂志 , 2025 , 31 ( 12 ): 140 - 149 .
WU Y T , WANG Z B , FU X Y , et al . Shenqi Dihuang decoction mediates ACSL4/LPCAT3/ALOX15 axis to inhibit arachidonic acid-related ferroptosis and improve renal function in diabetic nephropathy mice [J]. Chin J Exp Tradit Med Form , 2025 , 31 ( 12 ): 140 - 149 .
WANG S , CHEN Z , FU P , et al . Use of auricular acupressure to improve the quality of life in diabetic patients with chronic kidney diseases:A prospective randomized controlled trial [J]. Evid Based Complement Alternat Med , 2014 , 2014 ( 1 ): 343608 .
LI Q S , WANG X M , LI X C , et al . Research progress in the treatment of diabetes complications with Yiqi Huoxue prescriptions combined with acupuncture and moxibustion [J]. MEDS Chin Med , 2024 , 6 ( 2 ): 37 - 41 .
李娜 , 马钰 , 董奥 , 等 . 国医大师张大宁教授从“肾虚血瘀”辨证论治糖尿病肾脏病经验 [J]. 世界中西医结合杂志 , 2023 , 18 ( 4 ): 668 - 670,686 .
LI N , MA Y , DONG A , et al . Professor ZHANG Daning's experience in treating diabetic kidney disease based on "kidney deficiency and blood stasis" syndrome differentiation [J]. World J Integr Tradit West Med , 2023 , 18 ( 4 ): 668 - 670,686 .
陈亮 , 丁英钧 . 赵玉庸治疗糖尿病肾病经验 [J]. 中华中医药杂志 , 2020 , 35 ( 1 ): 244 - 247 .
CHEN L , DING Y J . ZHAO Yuyong's experience in treating diabetic nephropathy [J]. China J Tradit Chin Med Pharm , 2020 , 35 ( 1 ): 244 - 247 .
汪六林 , 李刚 , 程虹 , 等 . 当归芍药散治疗Ⅳ期糖尿病肾病的临床效果 [J]. 广西医学 , 2019 , 41 ( 15 ): 1910 - 1913 .
WANG LL , LI G , CHENG H , et al . Clinical effect of Danggui Shaoyaosan in treating stage Ⅳ diabetic nephropathy [J]. Guangxi Med J , 2019 , 41 ( 15 ): 1910 - 1913 .
LI X , MIAO X , WANG L , et al . Effect of Danggui Shaoyaosan on renal macrophages in STZ-induced DN rats [J]. J King Saud Univ Sci , 2020 , 32 ( 2 ): 1778 - 1784 .
PETRAZZUOLO A , SABIU G , ASSI E , et al . Broadening horizons in mechanisms,management,and treatment of diabetic kidney disease [J]. Pharmacol Res , 2023 , 190 : 106710 .
HU X , CHEN S , YE S , et al . New insights into the role of immunity and inflammation in diabetic kidney disease in the omics era [J]. Front Immunol , 2024 , 15 : 1342837 .
PAL R , BHADADA S K . AGEs accumulation with vascular complications,glycemic control and metabolic syndrome:A narrative review [J]. Bone , 2023 , 176 : 116884 .
ZHANG Y , LIANG X , BAO X , et al . Toll-like receptor 4(TLR4) inhibitors:Current research and prospective [J]. Eur J Med Chem , 2022 , 235 : 114291 .
KHAN D , BEDNER P , MÜLLER J , et al . TGF- β activated kinase 1(TAK1) is activated in microglia after experimental epilepsy and contributes to epileptogenesis [J]. Mol Neurobiol , 2023 , 60 ( 6 ): 3413 - 3422 .
OH A , PARDO M , RODRIGUEZ A , et al . NF- κ B signaling in neoplastic transition from epithelial to mesenchymal phenotype [J]. Cell Commun Signaling , 2023 , 21 ( 1 ): 291 .
MUSSBACHER M , DERLER M , BASÍLIO J , et al . NF- κ B in monocytes and macrophages-an inflammatory master regulator in multitalented immune cells [J]. Front Immunol , 2023 , 14 : 1134661 .
WILLIAMS B M , CLIFF C L , LEE K , et al . The role of the NLRP3 inflammasome in mediating glomerular and tubular injury in diabetic nephropathy [J]. Front Physiol , 2022 , 13 : 907504 .
QUE X , ZHENG S , SONG Q , et al . Fantastic voyage:The journey of NLRP3 inflammasome activation [J]. Genes Dis , 2024 , 11 ( 2 ): 819 - 829 .
ALIYU M , ZOHORA F T , ANKA A U , et al . Interleukin-6 cytokine:An overview of the immune regulation,immune dysregulation,and therapeutic approach [J]. Int Immunopharmacol , 2022 , 111 : 109130 .
XUE C , YAO Q , GU X , et al . Evolving cognition of the JAK-STAT signaling pathway:Autoimmune disorders and cancer [J]. Signal Transduction Targeted Ther , 2023 , 8 ( 1 ): 204 .
NIU Y , ZHANG Y , ZHANG W , et al . Canagliflozin ameliorates NLRP3 inflammasome-mediated inflammation through inhibiting NF- κ B signaling and upregulating bif-1 [J]. Front Pharmacol , 2022 , 13 : 820541 .
SINGH A K , FECHTNER S , CHOURASIA M , et al . Critical role of IL-1 α in IL-1 β -induced inflammatory responses:Cooperation with NF- κ B p65 in transcriptional regulation [J]. FASEB J:Off Publ Fed Am Soc Exp Biol , 2019 , 33 ( 2 ): 2526 - 2536 .
SARAIVA M , VIEIRA P . Biology and therapeutic potential of interleukin-10 [J]. J Exp Med , 2019 , doi: 10.1084/jem.20190418 http://dx.doi.org/10.1084/jem.20190418 .
CARLINI V , NOONAN D M , ABDALALEM E , et al . The multifaceted nature of IL-10:Regulation,role in immunological homeostasis and its relevance to cancer,COVID-19 and post-COVID conditions [J]. Front Immunol , 2023 , 14 : 1161067 .
KHAN A W , FAROOQ M , HWANG M J , et al . Autoimmune neuroinflammatory diseases:Role of interleukins [J]. Int J Mol Sci , 2023 , 24 ( 9 ): 7960 .
QUAN Y , SU P , SHANGGUAN C , et al . Bergenin ameliorates diabetic nephropathy in C57BL/6 J mice by TLR4/MyD88/NF- κ B signalling pathway regulation [J]. Toxicol Appl Pharmacol , 2023 , 475 : 116633 .
MA Q , HU X , LIU F , et al . A novel fusion protein consisting of anti-ANGPTL3 antibody and interleukin-22 ameliorates diabetic nephropathy in mice [J]. Front Immunol , 2022 , 13 : 1011442 .
CHEN Q , REN D , LIU L , et al . Ginsenoside compound K ameliorates development of diabetic kidney disease through inhibiting TLR4 activation induced by microbially produced imidazole propionate [J]. Int J Mol Sci , 2022 , 23 ( 21 ): 12863 .
YANG M , ZHAO L . The selective NLRP3-inflammasome inhibitor CY-09 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3-inflammasome activation [J]. Curr Med Chem , 2023 , 30 : 12863 .
0
浏览量
29
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
